Related Experiment Video

Updated: Apr 20, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K

Arginine deprivation in cancer therapy

Lynn G Feun1, Macus Tien Kuo, Niramol Savaraj

  • 1aSylvester Comprehensive Cancer Center, University of Miami, Miami, Florida bDepartment of Translational Molecular Pathology, The University of Texas MD, Anderson Cancer Center, Houston, Texas cSylvester Comprehensive Cancer Center, University of Miami, VA Medical Center, Miami, Florida, USA.

Current Opinion in Clinical Nutrition and Metabolic Care
|December 5, 2014
PubMed
Abstract

Insights

Arginine (Arg) deprivation shows promise for treating cancers by targeting Arg-dependent tumors. Research highlights new enzymes, resistance mechanisms, and ongoing clinical trials for this metabolic therapy.

Area of Science:

  • Oncology
  • Metabolic Therapy
  • Biochemistry

Background:

  • Metabolic therapy for cancer, specifically arginine (Arg) deprivation, is gaining renewed interest.
  • Arg-dependent malignancies are a focus, utilizing enzymes like arginase and Arg deiminase.

Purpose of the Study:

  • To review recent studies on Arg-dependent cancers and Arg-degrading enzymes.
  • To highlight advancements in understanding Arg metabolism in tumors.

Main Methods:

  • Review of recent scientific literature and clinical trials.
  • Analysis of gene expression, specifically argininosuccinate synthetase.
  • Investigation of tumor cell death mechanisms and resistance pathways.

Main Results:

  • Identification of argininosuccinate synthetase as a key downregulated gene in amino acid metabolism.
  • Elucidation of tumor cell death mechanisms induced by arginase and pegylated Arg deiminase.
  • Understanding of cancer resistance mechanisms to Arg deprivation therapy.

Conclusions:

  • Arginine deprivation represents a promising therapeutic strategy for various malignancies.
  • Ongoing clinical trials are evaluating Arg deprivation for advanced cancers.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

2.0K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.4K

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K